Australia · Delayed Price · Currency is AUD Aroa Biosurgery Statistics
Total Valuation
Aroa Biosurgery has a market cap or net worth of AUD 223.11 million. The enterprise value is 205.82 million.
| Market Cap | 223.11M |
| Enterprise Value | 205.82M |
Important Dates
The last earnings date was Tuesday, May 26, 2026.
| Earnings Date | May 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aroa Biosurgery has 345.90 million shares outstanding. The number of shares has increased by 5.39% in one year.
| Current Share Class | 345.90M |
| Shares Outstanding | 345.90M |
| Shares Change (YoY) | +5.39% |
| Shares Change (QoQ) | +10.74% |
| Owned by Insiders (%) | 25.12% |
| Owned by Institutions (%) | 33.38% |
| Float | 259.01M |
Valuation Ratios
The trailing PE ratio is 60.06 and the forward PE ratio is 52.25.
| PE Ratio | 60.06 |
| Forward PE | 52.25 |
| PS Ratio | 2.58 |
| PB Ratio | 2.70 |
| P/TBV Ratio | 3.12 |
| P/FCF Ratio | 28.40 |
| P/OCF Ratio | 25.41 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.27, with an EV/FCF ratio of 26.20.
| EV / Earnings | 52.85 |
| EV / Sales | 2.38 |
| EV / EBITDA | 24.27 |
| EV / EBIT | 43.52 |
| EV / FCF | 26.20 |
Financial Position
The company has a current ratio of 4.77, with a Debt / Equity ratio of 0.06.
| Current Ratio | 4.77 |
| Quick Ratio | 4.18 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.63 |
| Debt / FCF | 0.68 |
| Interest Coverage | 12.01 |
Financial Efficiency
Return on equity (ROE) is 4.86% and return on invested capital (ROIC) is 6.41%.
| Return on Equity (ROE) | 4.86% |
| Return on Assets (ROA) | 3.09% |
| Return on Invested Capital (ROIC) | 6.41% |
| Return on Capital Employed (ROCE) | 5.44% |
| Weighted Average Cost of Capital (WACC) | 8.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.90 |
| Inventory Turnover | 2.10 |
Taxes
In the past 12 months, Aroa Biosurgery has paid 495,375 in taxes.
| Income Tax | 495,375 |
| Effective Tax Rate | 11.28% |
Stock Price Statistics
The stock price has increased by +29.00% in the last 52 weeks. The beta is 0.84, so Aroa Biosurgery's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | +29.00% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 53.28 |
| Average Volume (20 Days) | 224,516 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aroa Biosurgery had revenue of AUD 86.47 million and earned 3.89 million in profits. Earnings per share was 0.01.
| Revenue | 86.47M |
| Gross Profit | 73.95M |
| Operating Income | 4.73M |
| Pretax Income | 4.39M |
| Net Income | 3.89M |
| EBITDA | 7.36M |
| EBIT | 4.73M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 22.59 million in cash and 5.31 million in debt, with a net cash position of 17.28 million or 0.05 per share.
| Cash & Cash Equivalents | 22.59M |
| Total Debt | 5.31M |
| Net Cash | 17.28M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 82.71M |
| Book Value Per Share | 0.24 |
| Working Capital | 50.85M |
Cash Flow
In the last 12 months, operating cash flow was 8.78 million and capital expenditures -923,313, giving a free cash flow of 7.86 million.
| Operating Cash Flow | 8.78M |
| Capital Expenditures | -923,313 |
| Depreciation & Amortization | 2.59M |
| Net Borrowing | -1.11M |
| Free Cash Flow | 7.86M |
| FCF Per Share | 0.02 |
Margins
Gross margin is 85.53%, with operating and profit margins of 5.47% and 4.50%.
| Gross Margin | 85.53% |
| Operating Margin | 5.47% |
| Pretax Margin | 5.08% |
| Profit Margin | 4.50% |
| EBITDA Margin | 8.51% |
| EBIT Margin | 5.47% |
| FCF Margin | 9.09% |
Dividends & Yields
Aroa Biosurgery does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.39% |
| Shareholder Yield | -5.39% |
| Earnings Yield | 1.75% |
| FCF Yield | 3.52% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Aroa Biosurgery is 1.08, which is 67.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1.08 |
| Price Target Difference | 67.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 15.04% |
| EPS Growth Forecast (3Y) | 48.22% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Aroa Biosurgery has an Altman Z-Score of 7.78 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.78 |
| Piotroski F-Score | 6 |